{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Genmab A/S"},"Symbol":{"label":"Symbol","value":"GMAB"},"Address":{"label":"Address","value":"KALVEBOD BRYGGE 43, COPENHAGEN V, 1560, Denmark"},"Phone":{"label":"Phone","value":"+45 70202728"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered wth Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications."},"CompanyUrl":{"label":"Company Url","value":"https://www.genmab.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Jan G. J. van de Winkel","title":"President & Chief Executive Officer"},{"name":"Rayne Waller","title":"Chief Technology Officer & Executive VP"},{"name":"Tahamtan Ahmadi","title":"Chief Medical Officer & Executive Vice President"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}